prazosin and s 1033
prazosin has been researched along with s 1033 in 4 studies
Research
Studies (4)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Boumendjel, A; Creczynski-Pasa, TB; Di Pietro, A; Gauthier, C; Gozzi, G; Lecerf-Schmidt, F; Lightbody, M; Ozvegy-Laczka, C; Peres, B; Sarkadi, B; Szakacs, G; Winter, E | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Eadie, L; Hughes, TP; White, DL | 1 |
| Eadie, LN; Hughes, TP; White, DL | 1 |
Reviews
1 review(s) available for prazosin and s 1033
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Other Studies
3 other study(ies) available for prazosin and s 1033
| Article | Year |
|---|---|
Structure-activity relationships of chromone derivatives toward the mechanism of interaction with and inhibition of breast cancer resistance protein ABCG2.
Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Chromones; Dose-Response Relationship, Drug; Humans; Molecular Structure; Neoplasm Proteins; Structure-Activity Relationship | 2013 |
Nilotinib does not significantly reduce imatinib OCT-1 activity in either cell lines or primary CML cells.
Topics: Adrenergic alpha-Antagonists; Benzamides; Drug Therapy, Combination; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Octamer Transcription Factor-1; Piperazines; Prazosin; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Tetraethylammonium; Tumor Cells, Cultured | 2010 |
Patients with low OCT-1 activity and high ABCB1 fold rise have poor long-term outcomes in response to tyrosine kinase inhibitor therapy.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Octamer Transcription Factor-1; Prazosin; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; RNA, Messenger | 2018 |